Author:
Zhang Hong,Wu Min,Zhu Xiaoxue,Li Cuiyun,Li Xiaojiao,Jin Weili,Zhang Dengke,Chen Hong,Liu Chengjiao,Ding Yanhua,Niu Junqi,Liu Jingrui
Funder
National Major Scientific and Technological Special Project
National Natural Science Foundation of China
Xi'an Xintong research Co Ltd.
Reference30 articles.
1. Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection;Agarwal;J. Hepatol.,2015
2. Buti M2, Chan HLY. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection;Agarwal;J. Hepatol.,2018
3. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial;Chan;Lancet Gastroenterol. Hepatol.,2016
4. Correlation between tenofovir drug levels and the renal biomarkers RBP-4 and ß2M in the ION-4 study cohort;Chan;Open Forum Infect. Dis.,2019
5. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level;Chen;J. Am. Med. Assoc.,2006
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献